Sphera Funds Management
Sphera Funds Management reported 97 stocks worth $699M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are Teva Pharmaceutical Inds Ltd (7.3%), MLYS (5.7%) and TSEM (4.0%). Compared with Q1 2026, the fund opened new positions in INSM, RYTM and LRCX, added to MLYS, SNDX and BIIB, trimmed TSEM, RARE and NVMI and sold out of CLBT, PANW and CAMT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | TEVA PHARMACEUTICAL INDS LTD | $50.8M | 7.3% | 1.5M | +363K (+32%) | 8 of 8 | |
| 2 |  MLYS Mineralys Therapeutics Inc | $39.7M | 5.7% | 1.5M | +130K (+10%) | 8 of 8 | |
| 3 |  TSEM Tower Semiconductor Ltd | $28.2M | 4.0% | 108K | −37K (−26%) | 8 of 8 | |
| 4 |  SNDX Syndax Pharmaceuticals Inc | $22.2M | 3.2% | 1M | +290K (+40%) | 8 of 8 | |
| 5 |  BIIB Biogen Inc | $20.9M | 3.0% | 97K | +4,100 (+4%) | 8 of 8 | |
| 6 |  RARE Ultragenyx Pharmaceutical in | $19.6M | 2.8% | 588K | −221K (−27%) | 8 of 8 | |
| 7 |  BMRN Biomarin Pharmaceutical Inc | $18.8M | 2.7% | 329K | +189K (+135%) | 3 of 8 | |
| 8 |  CYTK Cytokinetics Inc | $18.7M | 2.7% | 220K | +180K (+452%) | 8 of 8 | |
| 9 |  BBIO Bridgebio Pharma Inc | $18.3M | 2.6% | 245K | No change | 8 of 8 | |
| 10 |  COGT Cogent Biosciences Inc | $17.8M | 2.5% | 459K | +43K (+10%) | 6 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
AMICUS THERAPEUTICS INC | $8.7M | 603K |
 CLBT Cellebrite DI Ltd | $8.7M | 632K |
APELLIS PHARMACEUTICALS INC | $8.6M | 215K |
 PANW Palo Alto Networks Inc | $8.5M | 53K |
 CAMT Camtek Ltd | $8M | 53K |
🔒 Free account: see all 17.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 XBI Spdr Series Trust | Put | $23.7M | 150K | −50,000 |
BIIB Biogen Inc | Call | $21.6M | 100K | +100,000 |
CYTK Cytokinetics Inc | Call | $8.5M | 100K | −159,300 |
 PRAX Praxis Precision Medicines I | Call | $4.2M | 13K | +12,500 |
 TLT Ishares TR | Call | $4.1M | 47K | 0 |
🔒 Free account: see all 8.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Sphera Funds Management 13F FAQ
What does Sphera Funds Management own?
Sphera Funds Management reported 97 stocks worth $699M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are Teva Pharmaceutical Inds Ltd (7.3%), MLYS (5.7%) and TSEM (4.0%). The table above lists every position in the filing (the top 10 without an account).
What did Sphera Funds Management buy and sell in Q2 2026?
Compared with Q1 2026: 22 new positions, 32 added to, 28 trimmed and 17 sold out. New positions include INSM, RYTM and LRCX. It sold all of CLBT, PANW and CAMT.
When will Sphera Funds Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Sphera Funds Management's portfolio worth?
The Q2 2026 filing reports $699M in US stocks ($767M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.